文献速递肝病

综述:肠肝轴中胆汁酸信号的治疗作用

Review article: therapeutic aspects of bile acid signalling in the gut-liver axis.
PubMed 文献 · Aliment Pharmacol Ther · 2021-09-23

本文综述胆汁酸作为肠道与肝脏间内分泌调节因子的信号通路及其治疗应用。胆汁酸信号维持肠道屏障完整性和抗菌防御,FXR激动剂在随机对照临床试验中对胆汁淤积性和代谢性肝病显示疗效,但在失代偿期肝硬化等晚期肝病中的效果尚待证实。

要点

  • 胆汁酸信号是肠肝轴串扰的核心,调控炎症、纤维化与内皮功能障碍相关转录网络。
  • FXR是胆汁酸信号的关键节点和治疗靶点。
  • FXR激动剂对胆汁淤积性和代谢性肝病有随机对照试验证据,晚期肝病待验证。

核心结论

  • 实验证据提示胆汁酸信号可改善肝硬化肠道屏障并防止细菌易位。
  • FXR激动剂在随机对照临床试验中对胆汁淤积性和代谢性肝病显示疗效,但在晚期肝病尤其是失代偿期肝硬化患者中尚待验证。

研究设计与样本

  • 本文为文献综述,检索并汇总胆汁酸信号及慢性肝病治疗应用的实验与临床研究。

主要发现

  • 肠道与肝脏胆汁酸信号通路共同维持胆汁酸稳态。
  • 胆汁酸介导的肠肝串扰紊乱会失调炎症、纤维化和内皮功能障碍相关转录网络。
  • 胆汁酸通过释放肠道激素诱导肠肝反馈信号并调节肠肝循环。
  • 胆汁酸信号在维持肠道屏障完整性和抗菌防御中起核心作用,在肝硬化中细菌易位对疾病进展影响深远。
  • 核胆汁酸法尼醇X受体(FXR)是胆汁酸信号的中心交叉点,已成为相关治疗靶点。

临床怎么用

  • 关注FXR激动剂在胆汁淤积性和代谢性肝病中的治疗应用。
  • 在晚期肝病尤其是失代偿期肝硬化中,胆汁酸信号治疗的效果尚不明确,需待进一步研究。

局限性

  • FXR激动剂在晚期肝病尤其是失代偿期肝硬化患者中的效果尚待证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bile acids are important endocrine modulators of intestinal and hepatic signalling cascades orchestrating critical pathophysiological processes in various liver diseases. Increasing knowledge on bile acid signalling has stimulated the development of synthetic ligands of nuclear bile acid receptors and other bile acid analogues. AIM: This review summarises important aspects of bile acid-mediated crosstalk between the gut and the liver ("gut-liver axis") as well as recent findings from experimental and clinical studies. METHODS: We performed a literature review on bile acid signalling, and therapeutic applications in chronic liver disease. RESULTS: Intestinal and hepatic bile acid signalling pathways maintain bile acid homeostasis. Perturbations of bile acid-mediated gut-liver crosstalk dysregulate transcriptional networks involved in inflammation, fibrosis and endothelial dysfunction. Bile acids induce enterohepatic feedback signalling by the release of intestinal hormones, and regulate enterohepatic circulation. Importantly, bile acid signalling plays a central role in maintaining intestinal barrier integrity and antibacterial defense, which is particularly relevant in cirrhosis, where bacterial translocation has a profound impact on disease progression. The nuclear bile acid farnesoid X receptor (FXR) is a central intersection in bile acid signalling and has emerged as a relevant therapeutic target. CONCLUSIONS: Experimental evidence suggests that bile acid signalling improves the intestinal barrier and protects against bacterial translocation in cirrhosis. FXR agonists have displayed efficacy for the treatment of cholestatic and metabolic liver disease in randomised controlled clinical trials. However, similar effects remain to be shown in advanced liver disease, particularly in patients with decompensated cirrhosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Simbrunner B, Trauner M, Reiberger T, et al. Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. Aliment Pharmacol Ther. 2021. PMID: 34555862. doi:10.1111/apt.16602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。